Filing search / Centessa Pharmaceuticals plc / "Innovation"

DEFA14A

CNTA Centessa Pharmaceuticals plc

20 May 24

Additional proxy soliciting materials

8:48pm

to continue to drive both innovation and long-term value for the benefit of all our stakeholders. Thank you for your support and trust in our company … affiliated with Medicxi or Index Ventures. Centessa operates as a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation

PRE 14A

CNTA Centessa Pharmaceuticals plc

26 Apr 24

Preliminary proxy

4:36pm

) David Grainger, former Chief Innovation Officer (13) Gregory Weinhoff, M.D., M.B.A. (14) David Chao, Ph.D. (15) Iqbal Hussain (16) Antoine Yver, M.D … agreements with drug discovery companies affiliated with David Grainger, former Chief Innovation Officer Certain Centessa subsidiaries have entered

424B5

w6vxj

24 Apr 24

Prospectus supplement for primary offering

8:53pm

424B5

onixmm

23 Apr 24

Prospectus supplement for primary offering

5:16pm

8-K

EX-99.2

sht7uncmp1

14 Aug 23

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

7:06am

8-K

EX-99.1

oyk3wl2dgut4yybznki8

9 Jun 23

Regulation FD Disclosure

7:10am

DEFA14A

nwkljs7uz1cktbsf1a3

23 May 23

Additional proxy soliciting materials

4:08pm

8-K

EX-99.2

yu9ziydoqoguffwglztx

30 Mar 23

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

7:19am

8-K

EX-99.1

obnhwp4t c875gy

12 Sep 22

Regulation FD Disclosure

7:16am